Email this page: News Release
Athersys Announces FDA Authorization of Phase II Clinical Trial for Inflammatory Bowel Disease With Pfizer Regenerative Medicine
To (email address):
Separate multiple addresses with commas. Maximum 200 characters.
Your email address:
These email addresses will be used to email the page on your behalf and will not be used by Athersys for any marketing purposes.
Add a comment:
Link to page
Type in number:
This helps Athersys prevent automated submissions.